The stock market question is whether PBYI is 8X better than ONTY? The two should be much more closely valued, and it seems that PBYI is the one most out of step.
Sentiment: Strong Sell
The difference between sense and nonsense is that sense has limits. $125,000 a year for near fatal diarrhea? I don't think so. "Global?" Give me a break. They are years away from US approval, even if everything goes as planned. Global revs will be 3-5 years away and, if ever, a fraction of $125k.
Thank you for the thoughtful reply. The issue here isn't binary... either the drug gets approved or it doesn't, either the next news is positive or negative. Nope, the issue is... even if everything goes perfectly for PBYI, at your wildest dreams, what kind of value do you put on a cancer drug (with side effects) that may help you live a couple months longer. Well, not $3.6 billion... especially with so much wood to chop before it might actually get approval. There are much better drugs in the collective pipeline not that far behind that will make PBYI obsolete in short order... again, even if everything goes as best as you can hope.
End of July... under $100. There is nothing that is going to rally this stock. Sure, there might be a couple of up days, even in a row. But this thing got way over inflated, and reality is settling in. This is a very mediocre drug with repelling side effects.
and diarrhea. The squirts are really hitting the fan now. Please tell me how you rationalize a $1 billion valuation? That's a $30 stock price. Could be below $100 before the end of the month.
This stock is in a death spiral. Only buyers are short covers and day-traders trying to scalp a few pennies. Nobody in their right mind thinks this drug is worth $4 billion.